MCID: HYP005
MIFTS: 55

Hypokalemia

Categories: Blood diseases, Metabolic diseases

Aliases & Classifications for Hypokalemia

MalaCards integrated aliases for Hypokalemia:

Name: Hypokalemia 12 75 55 6 15
Potassium Deficiency 75 17 72
Potassium Deficiency Disorder 12 72
Hypopotassemia 12
Potassium 43

Classifications:



External Ids:

Disease Ontology 12 DOID:4500
NCIt 50 C34939
ICD10 33 E87.6
UMLS 72 C0032827 C1514284

Summaries for Hypokalemia

MedlinePlus : 43 Potassium is a mineral that your body needs to work properly. It is a type of electrolyte. It helps your nerves to function and muscles to contract. It helps your heartbeat stay regular. It also helps move nutrients into cells and waste products out of cells. A diet rich in potassium helps to offset some of sodium's harmful effects on blood pressure. Many people get all the potassium they need from what they eat and drink. Sources of potassium in the diet include Leafy greens, such as spinach and collards Fruit from vines, such as grapes and blackberries Root vegetables, such as carrots and potatoes Citrus fruits, such as oranges and grapefruit Your kidneys help to keep the right amount of potassium in your body. If you have chronic kidney disease, your kidneys may not remove extra potassium from the blood. Some medicines also can raise your potassium level. You may need a special diet to lower the amount of potassium that you eat.

MalaCards based summary : Hypokalemia, also known as potassium deficiency, is related to diabetes insipidus, nephrogenic, autosomal and apparent mineralocorticoid excess. An important gene associated with Hypokalemia is SLC12A3 (Solute Carrier Family 12 Member 3), and among its related pathways/superpathways are Peptide hormone metabolism and Metabolism of steroid hormones. The drugs Hydrochlorothiazide and Guaifenesin have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and testes, and related phenotypes are behavior/neurological and growth/size/body region

Wikipedia : 75 Hypokalemia is a low level of potassium (K+) in the blood serum. Mild low potassium does not typically... more...

Related Diseases for Hypokalemia

Diseases related to Hypokalemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1604)
# Related Disease Score Top Affiliating Genes
1 diabetes insipidus, nephrogenic, autosomal 32.5 SLC12A1 CASR AQP2
2 apparent mineralocorticoid excess 32.5 REN NR3C2 HSD11B2
3 liddle syndrome 1 32.4 REN NR3C2 HSD11B2
4 seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance 32.3 SLC12A3 KCNJ1 AQP2
5 gitelman syndrome 31.7 SLC12A3 SLC12A1 REN KCNJ1 CLCNKB CASR
6 hyperaldosteronism, familial, type i 31.6 REN POMC NR3C2 HSD11B2
7 pseudohyperkalemia, familial, 2, due to red cell leak 31.4 REN NR3C2 KCNJ1 ACE
8 pseudohypoaldosteronism, type i, autosomal recessive 31.3 REN NR3C2
9 adenoma 31.0 POMC HSD11B2 CASR
10 conn's syndrome 30.7 REN POMC NR3C2 HSD11B2 CYP17A1
11 bartter syndrome, type 3 30.7 SLC12A3 SLC12A1 REN KCNJ1 CLCNKB BSND
12 bartter disease 30.7 SLC12A3 SLC12A1 REN KCNJ1 CLCNKB CASR
13 hypertension, diastolic 30.4 REN ACE
14 adrenal adenoma 30.3 REN POMC CYP17A1
15 malignant hypertension 30.3 REN ACE
16 hypoaldosteronism 30.2 REN POMC ACE
17 inappropriate adh syndrome 30.2 REN POMC AQP2
18 lipoid congenital adrenal hyperplasia 30.2 REN POMC CYP17A1
19 fibromuscular dysplasia 30.0 REN ACE
20 familial glucocorticoid deficiency 30.0 REN POMC
21 diabetes insipidus 30.0 SLC12A1 REN POMC AQP2
22 acute adrenal insufficiency 30.0 REN POMC
23 premenstrual tension 29.9 REN POMC
24 renal hypertension 29.8 SLC12A3 REN ACE
25 familial hypertension 29.8 REN NR3C2 HSD11B2
26 adrenal cortical hypofunction 29.8 REN POMC
27 autosomal dominant polycystic kidney disease 29.6 REN AQP2 ACE
28 congestive heart failure 29.6 REN NR3C2 ACE
29 polycystic kidney disease 29.6 REN AQP2 ACE
30 polyhydramnios 29.6 SLC12A1 KCNJ1 CLCNKB
31 adrenal carcinoma 29.6 REN POMC CYP17A1
32 syndrome of inappropriate antidiuretic hormone 29.6 POMC AQP2 ACE
33 pseudohypoaldosteronism 29.5 SLC12A3 REN NR3C2 KCNJ1
34 adrenocortical carcinoma, hereditary 29.5 POMC HSD11B2 CYP17A1
35 antenatal bartter syndrome 29.5 SLC12A1 REN KCNJ1 BSND
36 hepatorenal syndrome 29.5 REN AQP2 ACE
37 heart valve disease 29.4 REN NR3C2 ACE
38 arthrogryposis, distal, type 3 29.4 SLC12A3 REN NR3C2
39 bartter syndrome, type 2, antenatal 29.2 NR3C2 KCNJ1 CASR
40 kidney disease 29.0 REN NR3C2 CASR AQP2 ACE
41 idiopathic edema 29.0 NR3C2 AQP2 ACE
42 nephrocalcinosis 28.9 SLC12A3 SLC12A1 KCNJ1 HSD11B2 CLCNKB CASR
43 anuria 28.7 REN NR3C2 HSD11B2 ACE
44 hypertension, essential 28.7 SLC12A3 SLC12A1 REN NR3C2 HSD11B2 ACE
45 systolic heart failure 28.5 NR3C2 ACE
46 body mass index quantitative trait locus 11 28.4 POMC NR3C2 KCNH2 HSD11B2
47 myotonia, potassium-aggravated 12.8
48 potassium dichromate allergic contact dermatitis 12.4
49 sodium-potassium-atpase activity of red cell 12.3
50 obsolete: channelopathy due to a voltage-gated potassium channel defect 12.1

Graphical network of the top 20 diseases related to Hypokalemia:



Diseases related to Hypokalemia

Symptoms & Phenotypes for Hypokalemia

MGI Mouse Phenotypes related to Hypokalemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.21 ACE AQP2 BSND CACNA1S CASR CYP17A1
2 growth/size/body region MP:0005378 10.15 ACE AQP2 BSND CACNA1S CASR CYP17A1
3 cardiovascular system MP:0005385 10.14 ACE BSND CACNA1S HSD11B2 KCNH2 KCNJ1
4 homeostasis/metabolism MP:0005376 10.13 ACE AQP2 BSND CACNA1S CASR CLCNKB
5 hematopoietic system MP:0005397 9.97 ACE AQP2 BSND CASR KCNJ1 NR3C2
6 mortality/aging MP:0010768 9.97 ACE AQP2 BSND CACNA1S CASR CYP17A1
7 muscle MP:0005369 9.43 CACNA1S CASR HSD11B2 KCNH2 NR3C2 REN
8 renal/urinary system MP:0005367 9.4 ACE AQP2 BSND CASR CLCNKB HSD11B2

Drugs & Therapeutics for Hypokalemia

Drugs for Hypokalemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 988)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
2
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
3
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
4
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
5
Succinylcholine Approved Phase 4 306-40-1 5314
6
Diazoxide Approved Phase 4 364-98-7 3019
7
Epirubicin Approved Phase 4 56420-45-2 41867
8
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
9
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
10
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
11
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
12
Povidone-iodine Approved Phase 4 25655-41-8
13
Sodium citrate Approved, Investigational Phase 4 68-04-2
14
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
15
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
16
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
17
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
18
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
19
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
20
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
21
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
22
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
23
Chlorothiazide Approved, Vet_approved Phase 4 58-94-6 2720
24
Racepinephrine Approved Phase 4 329-65-7 838
25
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
26
Norepinephrine Approved Phase 4 51-41-2 439260
27
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
28
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 130881 158781
29
Ephedrine Approved Phase 4 299-42-3 9294
30
Pseudoephedrine Approved Phase 4 90-82-4 7028
31
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
32
Ceftazidime Approved Phase 4 78439-06-2, 72558-82-8 5481173
33
Clarithromycin Approved Phase 4 81103-11-9 84029
34
Allopurinol Approved Phase 4 315-30-0 2094
35
Glyburide Approved Phase 4 10238-21-8 3488
36
Hydrogen peroxide Approved, Vet_approved Phase 4 7722-84-1 784
37
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
38
Glycerol Approved, Investigational Phase 4 56-81-5 753
39
Thymol Approved Phase 4 89-83-8 6989
40
Prucalopride Approved Phase 4 179474-81-8
41
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
42
Phenylephrine Approved Phase 4 59-42-7 6041
43
Morphine Approved, Investigational Phase 4 57-27-2 5288826
44
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
45
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
46
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
47
Naftifine Approved Phase 4 65472-88-0 73342 47641
48
Azithromycin Approved Phase 4 83905-01-5 447043 55185
49 Tomato Approved Phase 4
50
Nicotinamide Approved, Investigational Phase 4 98-92-0 936

Interventional clinical trials:

(show top 50) (show all 1642)
# Name Status NCT ID Phase Drugs
1 Efficacy of KCl Plus 0.9%NaCl Compare With KCl Plus 0.45%NaCl for Correction of Hypokalemia in Hospitalized Patients Unknown status NCT02721095 Phase 4
2 Comparison of Enteral Versus Intravenous Potassium Supplementation in Hypokalemia in Post Cardiac Surgery Pediatric Cardiac Intensive Care Patients - Prospective Open Label Randomized Control Trial Unknown status NCT02015962 Phase 4 Intravenous potassium chloride;Oral potassium chloride
3 The Prevention of Refeeding Syndrome by a Diet Regime in Patient With Head and Neck Cancer Unknown status NCT01845922 Phase 4
4 Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis—a Multicentre, Prospective, Double-blind, Double-dummy, Randomized Controlled Clinical Trial Unknown status NCT02063100 Phase 4 Shenyankangfu tablets;Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 100mg;Losartan potassium 100mg
5 Comparison of High-dose Furosemide Versus the Combination of Low-dose Furosemide and Low-dose Dopamine in Patients With Acute Decompensated Heart Failure Unknown status NCT00937092 Phase 4 Furosemide;low-dose dopamine + low-dose furosemide
6 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
7 Does Aldosterone Cause Hypertension by a Non-Renal Mechanism? Unknown status NCT00553722 Phase 4 Eplerenone;Placebo
8 IM Ketorolac vs Diclofenac Potassium Powder for Oral Solution (Cambia) for the Acute Treatment of Severe Migraine Unknown status NCT02664116 Phase 4 Diclofenac postassium powder for oral solution and placebo injection;Ketorolac intramuscular injection and placebo oral solution
9 Comparison of Plasmalyte A, Normal Saline and Ringer Lactate as Intraoperative Fluids in Patients Undergoing Renal Transplantation. Unknown status NCT03115060 Phase 4 intravenous fluid administration WITH NORMAL SALINE, PLASMALYTE A, OR RINGER LACTATE
10 Neoadjuvant Epirubicin-cyclophosphamide-S-1 (ECS) Versus Epirubicin-cyclophosphamide-5-FU (ECF) in Local Advanced Breast Cancer Unknown status NCT01849380 Phase 4 S-1;5-FU
11 Efficacy Study of Nicorandil on Neointima After Coronary Drug-eluting Stent Implantation in Patients With Diabetic Mellitus Unknown status NCT02328521 Phase 4 Nicorandil;nicorandil placebo
12 Efficacy of Sustained-release Oral Dalfampridine on Upper Extremity Function in Patients With Multiple Sclerosis: a Pilot Study Unknown status NCT02259361 Phase 4 Sustained-release oral dalfampridine;Placebo
13 Safety of Amiodarone and Ranolazine Together in Patients With Stable Angina Unknown status NCT01558830 Phase 4 ranolazine;placebo
14 Assessment of the Effects of the Combination of Spironolactone to Conventional Pharmacotherapy in Dialysis Patients Unknown status NCT01128101 Phase 4 Spironolactone
15 Effects of Spironolactone on Collagen Metabolism in Pulmonary Arterial Hypertension Unknown status NCT01468571 Phase 4 Spironolactone;Placebo
16 Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients With Persistent Atrial Fibrillation Unknown status NCT00613496 Phase 4 irbesartan;placebo
17 Remission From Stage D Heart Failure (RESTAGE-HF) Unknown status NCT01774656 Phase 4 Pharmacological Treatment
18 Helicobacter Pylori Eradication Using a Bismuth Quadruple Therapy Among Asymptomatically Infected Adults in El Paso, Texas: A Pilot Study. Unknown status NCT01335334 Phase 4 bismuth subcitrate potassium, metronidazole,tetracycline hydrochloride and omeprazole
19 Renal Effects of Levosimendan in Patients Admitted With Acute Decompensated Heart Failure Unknown status NCT00527059 Phase 4 Levosimendan in addition to standard therapy;spironolactone, beta-blockers,ecc
20 Gut-kidney Axis: Renal Effects of Meditarranean Diet and Low-protein Diet With Ketoacids to Restore Physiological Intestinal Mibrobiota in Chronic Kidney Disease Unknown status NCT02302287 Phase 4
21 The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme, a Randomised Controlled Trial Unknown status NCT01429779 Phase 4 Movicol
22 Effect of Early Administration of Intracoronary Nicorandil Via Thrombus Aspiration Catheter Device During Primary Percutaneous Coronary Intervention for the Patients of Acute ST Segment Elevation Myocardial Infarction Unknown status NCT02435797 Phase 4 Nicorandil;normal saline
23 A Comparative Study to Assess the Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment naïve Patients of Chronic Stable Angina. Unknown status NCT01397994 Phase 4 Nicorandil;Atenolol
24 Impact of a Mineralocorticoid Receptor Antagonist on Chronic Histological Changes in Renal Allograft Unknown status NCT01510795 Phase 4 spironolactone
25 Effect of Aliskiren 300mg and Hydrochlorothiazide 25mg on Kidney Oxygenation in Patients With Stage 1 and 2 Hypertension: a BOLD-MRI Study Unknown status NCT01519635 Phase 4 Aliskiren;Hydrochlorothiazide
26 Effectiveness of Nano-hydroxyapetite Care Paste in Reducing Dentinhypersenstitivity: A Double Blind Randomized Control Trial Unknown status NCT02936830 Phase 4 5% Sodium Fluoride Varnish;15% Nanohydroxyapetite paste;Glycerol
27 The Optimal Dose Of Dexamethasone To Be Used As An Adjuvant To Low Volume Bupivacaine Ultrasound Guided Supraclavicular Brachial Plexus Block. A Randomized Controlled Double Blinded Dose Ranging Study Unknown status NCT03043495 Phase 4 Dexamethasone
28 A Clinical Study on Anti-Hypertensive Agent (ACEi) and Heart Function Improvement Unknown status NCT01069042 Phase 4 Enalapril
29 Clinical Effectiveness of Serum Chromogranin A (CgA) Levels on Diagnostic Relevance, Response After Surgical Resection and Recurrence of Pancreatic Endocrine Tumors (PET) Unknown status NCT02759718 Phase 4
30 Long-term Sulfonylurea Response and Glucose Control After Switching From Insulin in Children With Diabetes Due to ABCC8 (SUR1) Mutations Unknown status NCT02624830 Phase 4 Sulfonylurea
31 Bilateral Transversus Abdominis Plane Block With or Without Magnesium for Total Abdominal Hysterectomy With or Without Salpingo-oophorectomy: a Randomized Controlled Trial Unknown status NCT02680626 Phase 4 Magnesium Sulfate;Ropivacaine
32 Glucose Control During Labour in Gestational Diabetes Mellitus With Insulin Treatment: Insulin-Glucose-Infusion Versus Observational Approach - Is There a Difference in Neonatal Hypoglycemia Rate? Unknown status NCT02590016 Phase 4 Insulin, Aspart
33 Use of Diazoxide in Acute Hypoglycaemia Unknown status NCT01488136 Phase 4 Diazoxide;Placebo
34 The RECONSTRUCT Study - Reconstructing Disease Mechanisms in Asthma Unknown status NCT03034005 Phase 4 Budesonide
35 The Determinants of the Effectiveness of the Use of Furosemide in Patients on Dialysis Unknown status NCT01815892 Phase 4 Withdrawal of furosemide;furosemide administration
36 Prospective, Interventional, Single Arm Study in Outpatients Undergoing Sigmoidoscopy for Evaluation of Efficacy and Safety of Kleen Enema 120ml (Phosphate Enema) Unknown status NCT02386904 Phase 4 Phosphate Enema (Kleen® Enema)
37 The Role of Inflammatory and Stress Response in the Pathogenesis of Cognitive Dysfunction After Cardiac Surgery Unknown status NCT02767713 Phase 4 Dexamethasone
38 Efficacy of L-arginine Treatment on Blood Pressure Control Patients With Stage 1 Hypertension Unknown status NCT02894723 Phase 4
39 Randomised Study to Compare the Regain of Gastrointestinal Motility After General Anaesthesia Versus Spinal Anaesthesia in Caesarean Section.Kasr El Ainy,Egypt Experience Unknown status NCT02504749 Phase 4
40 An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
41 Evaluation of High-dose Corticosteroids on Microcirculation Alterations in Cardiac Surgery, by FMD (Flow Mediated vasoDilation), Near Infrared Spectrophotometry (NIRS) and Biological Analysis (Syndecan-1) Unknown status NCT02798068 Phase 4 Solu-medrol or placebo administration
42 Endoesophageal Cryotherapy: A New Technique For Ablating Barrett's Esophagus And Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
43 Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension Unknown status NCT02057328 Phase 4 TELMISARTAN;NEBIVOLOL
44 Effect of Licorice and Hydrochlorothiazide on Plasma Potassium Completed NCT00605202 Phase 4 Hydrochlorothiazide
45 Fluid Therapy in Acutely Ill Children - a Randomized Controlled Trial Completed NCT02926989 Phase 4 Plasmalyte Glucos 50 mg/mL;0.45% saline in 5% dextrose
46 Monocentric STUDY, Randomised Double Blinded (Healthy Subjects, or Transversal (Patients With Gitelman Syndrome) Completed NCT02297048 Phase 4
47 Assessing the Safety of a Continuous Potassium Chloride Infusion in Critical Care: A Randomised Controlled Trial Completed NCT00718068 Phase 4 Sterile Potassium Chloride Concentrate;Sterile Potassium Chloride Concentrate
48 Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter Completed NCT01818583 Phase 4 Potassium chloride;Glucose 50 MG/ML
49 The Effects of Dexmedetomidine on Myocardial Repolarization in Children Completed NCT02353169 Phase 4 Dexmedetomidine
50 Acetazolamide and Hydrochlorothiazide Followed by Furosemide Versus Hydrochlorothiazide and Furosemide Followed by Furosemide for the Treatment of Adults With Refractory Nephrotic Edema: A Randomized, Double-Blind Trial Completed NCT02427880 Phase 4 Acetazolamide and Hydrochlorothiazide Followed by Furosemide;Furosemide and Hydrochlorothiazide Followed by Furosemide

Search NIH Clinical Center for Hypokalemia

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Amiloride
Potassium acetate
Potassium chloride
Spironolactone

Genetic Tests for Hypokalemia

Anatomical Context for Hypokalemia

MalaCards organs/tissues related to Hypokalemia:

41
Heart, Kidney, Testes, Liver, Prostate, Lung, Brain

Publications for Hypokalemia

Articles related to Hypokalemia:

(show top 50) (show all 7695)
# Title Authors PMID Year
1
Distal tubule basolateral potassium channels: cellular and molecular mechanisms of regulation. 38 17
29894319 2018
2
Assessment and misassessment of potassium, phosphorus, and protein in the hemodialysis diet. 17
29813179 2018
3
Beneficial Effects of High Potassium: Contribution of Renal Basolateral K+ Channels. 17
29712740 2018
4
Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism. 9 38
20119883 2010
5
Feline primary hyperaldosteronism. 9 38
20219494 2010
6
Juxtaglomerular cell tumor of the kidney--a new classification scheme. 9 38
19914097 2010
7
Distal potassium handling based on flow modulation of maxi-K channel activity. 9 38
19448535 2009
8
Analysis of claudin genes in pediatric patients with Bartter's syndrome. 9 38
19538297 2009
9
The (+)- and (-)-gossypols potently inhibit human and rat 11beta-hydroxysteroid dehydrogenase type 2. 9 38
19150652 2009
10
Bartter's syndrome with type 2 diabetes mellitus. 9 38
19251537 2009
11
Diagnostic accuracy of adrenal venous sampling in comparison with other parameters in primary aldosteronism. 9 38
18497447 2008
12
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. 9 38
18645193 2008
13
[Severe hypokalemia after holidays return]. 9 38
19055123 2008
14
Gitelman syndrome. 9 38
18667063 2008
15
Selection of patients for surgery for primary aldosteronism. 9 38
18307754 2008
16
Changes of liver and muscle enzymes activity in patients with rigor. 9 38
18249306 2008
17
Reninoma: case report and literature review. 9 38
18192852 2008
18
Novel mutations in the SLC12A3 gene causing Gitelman's syndrome in Swedes. 9 38
17654016 2007
19
[11beta-hydroxysteroide dehydrogenases. Recent advances]. 9 38
17368420 2007
20
[Clinical significance of thiazide-sensitive Na-Cl cotransporter gene by mutational analysis]. 9 38
17511264 2007
21
Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess. 9 38
17314322 2007
22
A compound heterozygous mutation in the CYP17 (17alpha-hydroxylase/17,20-lyase) gene in a Chinese subject with congenital adrenal hyperplasia. 9 38
17379008 2007
23
P450c17 deficiency: clinical and molecular characterization of six patients. 9 38
17192295 2007
24
Severe hypokalemia, rhabdomyolysis, muscle paralysis, and respiratory impairment in a hypertensive patient taking herbal medicines containing licorice. 9 38
17473492 2007
25
Loss of consciousness and hypokalemia in an elderly man with a mutation of the thiazide-sensitive Na-Cl cotransporter gene. 9 38
16966826 2006
26
Inherited renal tubulopathies associated with metabolic alkalosis: effects on blood pressure. 9 38
17275579 2006
27
Cortisol metabolism in hypertension. 9 38
16980198 2006
28
Clinical review: Thyrotoxic periodic paralysis: a diagnostic challenge. 9 38
16608889 2006
29
A patient with cystinosis presenting transient features of Bartter syndrome. 9 38
17172073 2006
30
A novel compound heterozygous mutation of K494_V495 deletion plus R496L and D487_F489 deletion in extreme C-terminus of cytochrome P450c17 causes 17alpha-hydroxylase deficiency. 9 38
16483711 2006
31
Genetic variations of HSD11B2 in hypertensive patients and in the general population, six rare missense/frameshift mutations. 9 38
16778331 2006
32
A novel mutation of the thiazide-sensitive sodium chloride cotransporter gene in a Japanese family with Gitelman syndrome. 9 38
16429844 2006
33
Chondrocalcinosis secondary to hypomagnesemia in Gitelman's syndrome. 9 38
16142886 2005
34
VIPomas: an update in diagnosis and management in a series of 11 patients. 9 38
16001675 2005
35
A rare case of Gitelman's syndrome presenting with hypocalcemia and osteopenia. 9 38
16075932 2005
36
Evolution of diagnostic criteria for primary aldosteronism: why is it more common in "drug-resistant" hypertension today? 9 38
15527695 2004
37
G2736A polymorphism of thiazide-sensitive Na-Cl cotransporter gene predisposes to hypertension in young women. 9 38
15480096 2004
38
The syndromes of low-renin hypertension: "separating the wheat from the chaff". 9 38
15761538 2004
39
Apparent mineralocorticoid excess syndrome: an overview. 9 38
15761540 2004
40
Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency. 9 38
14715827 2004
41
Stimulation of NHE3 in OKP cells by an autocrine mechanism. 9 38
14752245 2004
42
P450c17 deficiency in Brazilian patients: biochemical diagnosis through progesterone levels confirmed by CYP17 genotyping. 9 38
14671162 2003
43
[Chondrocalcinosis and hypomagnesaemia in a patient with a new mutation in the gene of the thiazide-sensitive Na-Cl cotransporter]. 9 38
15002785 2003
44
Successful treatment of primary aldosteronism due to computed tomography-negative microadenoma. 9 38
14516402 2003
45
Hypertension and the cortisol-cortisone shuttle. 9 38
12788832 2003
46
Two homozygous mutations in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. 9 38
12788846 2003
47
A new mutation, R563Q, of the beta subunit of the epithelial sodium channel associated with low-renin, low-aldosterone hypertension. 9 38
12714866 2003
48
Cushing's syndrome from ectopic production of corticotropin by a metastatic gastrinoma. 9 38
12917066 2003
49
New aspects on primary aldosteronism. 9 38
12608705 2003
50
A calcitonin and vasoactive intestinal peptide-producing pancreatic endocrine tumor associated with the WDHA syndrome. 9 38
14716055 2003

Variations for Hypokalemia

ClinVar genetic disease variations for Hypokalemia:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 SLC12A3 NM_000339.3(SLC12A3): c.2221G> A (p.Gly741Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs138977195 16:56921879-56921879 16:56887967-56887967
2 SLC12A3 NM_000339.3(SLC12A3): c.457G> A (p.Val153Met) single nucleotide variant Uncertain significance rs779074538 16:56902236-56902236 16:56868324-56868324

Expression for Hypokalemia

Search GEO for disease gene expression data for Hypokalemia.

Pathways for Hypokalemia

GO Terms for Hypokalemia

Cellular components related to Hypokalemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.7 SLC12A3 SLC12A1 REN KCNJ1 KCNH2 CLCNKB
2 membrane GO:0016020 9.47 SLC12A3 SLC12A1 REN NR3C2 KCNJ1 KCNH2
3 apical plasma membrane GO:0016324 9.46 SLC12A3 SLC12A1 CASR AQP2
4 integral component of membrane GO:0016021 10 SLC12A3 SLC12A1 KCNJ1 KCNH2 HSD11B2 CLCNKB

Biological processes related to Hypokalemia according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 ion transmembrane transport GO:0034220 9.8 SLC12A1 KCNJ1 CLCNKB BSND
2 ion transport GO:0006811 9.73 SLC12A3 SLC12A1 KCNJ1 KCNH2 CLCNKB CACNA1S
3 potassium ion transport GO:0006813 9.71 SLC12A1 KCNJ1 KCNH2
4 regulation of ion transmembrane transport GO:0034765 9.71 KCNJ1 KCNH2 CLCNKB CACNA1S
5 transmembrane transport GO:0055085 9.63 SLC12A3 SLC12A1 KCNH2 CLCNKB CACNA1S AQP2
6 regulation of blood pressure GO:0008217 9.61 REN POMC ACE
7 cell volume homeostasis GO:0006884 9.56 SLC12A3 SLC12A1
8 calcium ion import GO:0070509 9.55 CASR CACNA1S
9 potassium ion import across plasma membrane GO:1990573 9.54 SLC12A3 SLC12A1 KCNJ1
10 amyloid-beta metabolic process GO:0050435 9.52 REN ACE
11 angiotensin maturation GO:0002003 9.51 REN ACE
12 glucocorticoid biosynthetic process GO:0006704 9.48 HSD11B2 CYP17A1
13 chloride ion homeostasis GO:0055064 9.46 SLC12A3 SLC12A1
14 excretion GO:0007588 9.32 KCNJ1 CLCNKB
15 potassium ion homeostasis GO:0055075 9.13 SLC12A3 SLC12A1 KCNH2
16 chloride transmembrane transport GO:1902476 9.02 SLC12A3 SLC12A1 CLCNKB CASR BSND

Molecular functions related to Hypokalemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 voltage-gated ion channel activity GO:0005244 9.58 KCNJ1 KCNH2 CACNA1S
2 steroid binding GO:0005496 9.46 NR3C2 HSD11B2
3 inward rectifier potassium channel activity GO:0005242 9.43 KCNJ1 KCNH2
4 potassium:chloride symporter activity GO:0015379 9.32 SLC12A3 SLC12A1
5 cation:chloride symporter activity GO:0015377 9.26 SLC12A3 SLC12A1
6 sodium ion transmembrane transporter activity GO:0015081 9.16 SLC12A3 SLC12A1
7 voltage-gated chloride channel activity GO:0005247 9.07 CLCNKB
8 sodium:potassium:chloride symporter activity GO:0008511 8.96 SLC12A3 SLC12A1
9 sodium:chloride symporter activity GO:0015378 8.62 SLC12A3 SLC12A1

Sources for Hypokalemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....